Taking this into account, Truist upgraded its Sangamo Therapeutics Inc [SGMO] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in early December has reiterated a ‘”a Buy”‘ rating for it. RBC Capital Mkts also remained covering SGMO and has decreased its forecast on November 03, 2023 with a “Sector perform” recommendation from previously “an Outperform” rating. BofA Securities revised its rating on April 28, 2023. It rated SGMO as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of SGMO
On Monday, Sangamo Therapeutics Inc [NASDAQ:SGMO] saw its stock jump 6.66% to $0.75. Over the last five days, the stock has gained 3.72%. Sangamo Therapeutics Inc shares have fallen nearly -26.78% since the year began. Nevertheless, the stocks have risen 48.65% over the past one year. While a 52-week high of $3.18 was reached on 01/07/25, a 52-week low of $0.30 was recorded on 05/07/25. SMA at 50 days reached $0.7893, while 200 days put it at $1.2061.
Levels Of Support And Resistance For SGMO Stock
The 24-hour chart illustrates a support level at 0.7020, which if violated will result in even more drops to 0.6572. On the upside, there is a resistance level at 0.7770. A further resistance level may holdings at 0.8072. The Relative Strength Index (RSI) on the 14-day chart is 50.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0069, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.19%. Stochastics %K at 63.13% indicates the stock is a holding.
